Antiplatelet Therapy Continuation in Spine Surgery - Its Effect on Postoperative Morbidity and Mortality
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01006083|
Recruitment Status : Unknown
Verified October 2009 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Not yet recruiting
First Posted : November 2, 2009
Last Update Posted : November 2, 2009
|Condition or disease|
|Hemorrhage Cerebrovascular Accident Myocardial Infarction Pulmonary Embolism Deep Vein Thrombosis|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Impact of Continued Use of Clopidogrel and / or Aspirin on Outcomes in Patients Undergoing Lumbar Spine Surgery. A Prospective Observational Study|
|Study Start Date :||January 2010|
|Estimated Primary Completion Date :||January 2012|
|Estimated Study Completion Date :||February 2012|
Low-risk patients, not on APAs
Patients not at risk of coronary and/or cerebrovascular disease, and not consuming APAs
High-risk patients, not on APAs
Patients at high risk for cardio/cerebrovascular disease (diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertension, morbid obesity), but not taking APAs.
APA for primary prevention
High-risk patients with cardiovascular risk factors (as above), in whom APA is prescribed as primary prevention of coronary artery disease (CAD).
APA for secondary prevention
Patients with a history of a coronary syndrome (stable/unstable angina); MI; transient ischemic attack (TIA)/stroke; severe carotid artery stenosis/stenting; or peripheral vascular disease, on APAs for secondary prevention.
- Postoperative hemorrhagic, thrombotic, and neurological complications [ Time Frame: 60 days ]
- length of stay [ Time Frame: 30 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01006083
|Contact: Zvi Lidar, MDfirstname.lastname@example.org|
|Contact: Halil Salame, MDemail@example.com|
|Tel Aviv Sourasky medical center||Not yet recruiting|
|Tel Aviv, Israel, 64239|
|Sub-Investigator: Yifat Klein, PhD|
|Sub-Investigator: Zvi Lidar, MD|
|Sub-Investigator: Gilad Regev, MD|
|Sub-Investigator: Halil Salame, MD|
|Sub-Investigator: Uri Kenan, MD|
|Principal Investigator:||Idit Matot, MD||Tel-Aviv Sourasky Medical Center|